Supplements are taking on environmental toxins.
What’s happening: Denmark’s Cambiotics closed a ~€4M seed round led by Collaborative Fund to commercialize a probiotic designed to remove PFAS from the body.
Infiltrated. Embedded across modern life, “forever chemicals” are found in drinking water, food, cosmetics, and consumer goods. Accumulating over time, >95% of Americans carry detectable traces, with growing evidence linking exposure to chronic disease and elevated mortality risk.
Gut feeling. Fighting back, Cambiotics aims to reduce the body’s toxic load through the microbiome. After identifying a gut bacteria that absorbs PFAS at high levels, the biotech firm engineered a precision probiotic to help naturally expel the microbes.
The product, called 46&, will enter US clinical trials before launching later this year, initially targeting high-risk groups like firefighters, as well as health optimizers.
Unburdened. While regulation and product reform aim to stem exposure, emerging detox therapies—from sauna protocols to therapeutic plasma exchange and inhalants—are moving bioremediation into the mainstream.
As binder supplements like activated charcoal, bentonite, and chlorella gain popularity, Cambiotics will lean on scientific rigor and a partnership with Quest Diagnostics to prove its product’s efficacy.
Punchline: With the exposome becoming impossible to ignore, supercharging the body to fight human-made threats could become the new daily ritual.
